Burcu Uludağ

Burcu Uludağ

Auto-generated profile, based on publicly available information

Burcu Uludağ

Department of Cardiology, University of Health Sciences, Izmir City Hospital, İzmir, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in International Journal of the Cardiovascular Academy
Verified
Journal Article
Closed access
BUBurcu Uludağ
Burcu Uludağ
HSHatice Solmaz
Hatice Solmaz
YAYusuf İzzettin Alihanoğlu
Yusuf İzzettin Alihanoğlu
İKİsmail Doğu Kılıç
İsmail Doğu Kılıç
YEYaşar Enli
Yaşar Enli

1 October 2024 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
SDSami Deniz
Sami Deniz
BUBurcu Uludağ
Burcu Uludağ
FDFerhat Demirci
Ferhat Demirci
Vascular endothelial growth factor is a signaling protein created by cells performing important bodily functions. Vascular endothelial growth factor is abundant in the lung, and plasma levels are elevated in patients with severe pulmonary arterial hypertension. An association between soluble urokinase plasminogen activator receptor, an inflammatory biomarker, and soluble urokinase plasminogen activator receptor levels and interstitial pulmonary and vascular involvement (e.g., development of pulmonary hypertension) has been shown in SSc patients. The tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio, which has been recommended as a useful diagnostic tool in the last guideline, is one of the additional echocardiographic signs suggestive of pulmonary hypertension. We aimed to examine whether these biomarkers contribute to the diagnosis and management of pulmonary hypertension.


27 January 2025 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
SISinem İnAn
Sinem İnAn
SBSemra Bilaçeroǧlu
Semra Bilaçeroǧlu
BABurcu Uludağ Artun
Burcu Uludağ Artun
High blood levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) have been shown in various malignancies. In lung cancer, the importance of NT-proBNP is not clear. In this study, we aimed to investigate the significance of the correlation of NT-proBNP levels in lung cancer with tumor stage, tumor diameter, histopathology, and specific sites of mediastinal metastasis: lymphadenopathy; pericardial, cardiac, major vessel, other mediastinal organ or lymphatic involvement/invasion. A total of 105 lung cancer and 120 control patients (chronic obstructive lung disease, interstitial lung disease, pulmonary thromboembolism, and pneumonia; 30/subgroup) with measured NT-proBNP levels were included retrospectively. Demographics, comorbidities, and echocardiographic findings in all patients, as well as histologic subtype, diameter, stage, and radiologic and/or pathologic mediastinal involvement/invasion of the tumor to the mediastinum in patients with lung cancer, were studied with regard to blood NT-proBNP levels. When lung cancer and control groups were compared globally or as subgroups with comorbidities, NT-proBNP levels did not show meaningful differences. However, NT-proBNP levels were determined to be 249 pg/mL and 88 pg/mL in lung cancer (n=68) and control subgroups (n=58) without comorbidities, respectively (p=0.001). Among lung cancer patients without comorbidities and those with cardiac, pericardial, major vascular, or other mediastinal involvement/invasion (lymphadenopathy, lymphatic, or other organ invasion) (n=27), the NT-proBNP level was 303 pg/mL, whereas it was 166 pg/mL in those without these mediastinal invasions (n=41) (p=0.031). There is a need for much larger, randomized studies to obtain evidence for the potential role of NT-proBNP as a helpful diagnostic biomarker for lung cancer. Clinical suspicion of malignancy may be raised if high NT-proBNP levels cannot be explained by all other risk factors and disorders or diseases. Furthermore, pericardial, cardiac, major vessel, or other mediastinal invasion/involvement should be sought when high NT-proBNP levels are determined in lung cancer patients without any comorbidities or risk factors for high NT-proBNP levels.

23 September 2024 in İzmir Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
BUBurcu Uludağ
Burcu Uludağ
SYSerkan Yazgan
Serkan Yazgan
AÜAhmet Üçvet
Ahmet Üçvet
BABahar Agaoglu
Bahar Agaoglu
EŞEsra Yamansavcı Şirzai
Esra Yamansavcı Şirzai
KCKenan Can Ceylan
Kenan Can Ceylan
İmplante edilebilir kardiyak cihaz taşıyan hasta sayısı ve bu hastalara kalp dışı cerrahi uygulanma sıklığı giderek artmaktadır. Cihaz programlarının karmaşıklığı da gözönüne alındığında, bu hastaların perioperatif yönetimi zordur ve multidisipliner yaklaşımı gerektirmektedir. Cerrahi sırasında elektrokoter kullanımı kardiyak cihaz üzerinde elektromanyetik interferansa sebep olabilir ve bu durum ölüm dahil ciddi komplikasyonlara yol açabilir. Elektromanyetik interferansın önlenebilmesi için perioperatif dönemde doğru stratejinin uygulanması önemlidir. Bu derlemede, implante edilebilir kardiyak cihazlı hastaların güvenli perioperatif yönetimine dair bilgi sunulması amaçlanmıştır.

3 July 2026 in Medicine
Verified
Journal Article
Open access
HSHatice Solmaz
Hatice Solmaz
BUBurcu Uludag
Burcu Uludag
ACAyse Colak
Ayse Colak
The systemic immune-inflammation index (SII) is associated with the severity and progression of vascular disorders. However, the relationship between SII and chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. This study aimed to investigate for the first time the predictive value of SII for the development of CTEPH in patients with a history of unprovoked acute pulmonary embolism (PE). This retrospective case-control study included 62 patients with unprovoked acute PE for the first time. Thirty patients with CTEPH and 32 without CTEPH were compared in terms of baseline and follow-up clinical, echocardiographic, and laboratory parameters obtained at least 3 months after the index event. Univariate and multivariate logistic regression analyses were performed to determine predictors of CTEPH. The diagnostic performance of the SII was evaluated using receiver operating characteristic curve analysis. Among the baseline laboratory parameters related to SII, only platelet count (308 [237–339] vs 259 [207–283], P = .028) was significantly higher in the CTEPH group, whereas SII did not differ significantly between the groups. During follow-up beyond 3 months, neutrophil count (5.4 [3.6–6.4] vs 4 [3.3–4.8], P = .01), platelet count (313 [219–376] vs 251 [201–295], P = .02), and SII (1614 [607–2147] vs 566 [417–727], P < .001) were significantly higher, whereas lymphocyte count (1.4 ± 0.5 vs 1.9 ± 0.5, P < .001) was significantly lower in the CTEPH group. Multivariate logistic regression analysis demonstrated that the SII was an independent predictor of CTEPH (odds ratio 1.003 [1.000–1.005], P = .02). Receiver operating characteristic curve analysis showed that the SII had moderate diagnostic performance for predicting CTEPH (area under the curve = 0.797; 95% confidence interval, 0.682–0.912; P < .001), with an optimal cutoff value of 626.7. The SII may represent a practical and easily accessible biomarker for identifying patients at risk of developing CTEPH during follow-up after the first episode of unprovoked acute PE.